Skip to main content
SpringerLink
Log in

Secondary Hyperparathyroidism

  • Chapter
  • First Online:
Medical and Surgical Treatment of Parathyroid Diseases

  • 1045 Accesses

Abstract

Management of chronic kidney disease is often fraught with derangements in calcium and phosphorus metabolism. The development of secondary hyperparathyroidism begins in the early stage of CKD and usually progresses as the level of renal impairment advances. Treatment of SHPT is challenging and maintenance of calcium and phosphorus level is an important determinant of cardiovascular and bone health. In this chapter, we focus on the pathogenesis, etiology, and treatment of secondary hyperparathyroidism secondary to chronic kidney disease.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 129.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 169.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 249.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Druke TB. Cell biology of parathyroid gland hyperplasia in chronic renal failure. J Am Soc Nephrol. 2000;11:1141–52. Basic Science review, Level 1, Grade C.

    Google Scholar 

  2. Tominnaga Y, Tajagi J. Molecular genetics of hyperparathyroid disease. Curr Opin Nephrol Hypertens. 1996;5:336–41. Basic Science review, Level 1, Grade C.

    Article  Google Scholar 

  3. Fliser D, Kollerits B, Neyer U, Ankerst DP, Lhotta K, Lingenhel A, Ritz E, Kronenberg F, Kuen E, Konig P, Kraatz G, Mann JF, Muller GA, Kohler H, Riegler P. Fibroblast growth factor 23 (FGF23) predicts progression of chronic kidney disease: the Mild to Moderate Kidney Disease (MMKD) study. J Am Soc Nephrol. 2007;18:2600–8. Clinical Investigation, Level 3, Grade A.

    Article  CAS  PubMed  Google Scholar 

  4. Martinez I, Saracho R, Montenegro J, Llach F. The importance of dietary calcium and phosphorous in the secondary hyperparathyroidism of patients with early renal failure. Am J Kidney Dis. 1997;29(4):496–502. Clinical Investigation, Level 3, Grade A.

    Article  CAS  PubMed  Google Scholar 

  5. Hu MC, Shi M, Zhang J, Pastor J, Nakatani T, et al. Klotho: a novel phsophaturic substance acting as an autocrine enzyme in the renal proximal tubule. FASEB J. 2010;24(9):3438–50. Basic Science, Level 1, Grade A.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  6. Gutiérrez OM, Mannstadt M, Isakova T, Rauh-Hain JA, Tamez H, Shah A, Smith K, Lee H, Thadhani R, Jüppner H, Wolf M. Fibroblast growth factor 23 and mortality among patients undergoing hemodialysis. N Engl J Med. 2008;359(6):584–92. Clinical Investigation, Level 2, Grade A.

    Article  PubMed  PubMed Central  Google Scholar 

  7. Gutiérrez OM, Januzzi JL, Isakova T, Laliberte K, Smith K, Collerone G, Sarwar A, Hoffmann U, Coglianese E, Christenson R, Wang TJ, de Filippi C, Wolf M. Fibroblast growth factor 23 and left ventricular hypertrophy in chronic kidney disease. Circulation. 2009;119(19):2545–52. Clinical Investigation, Level 2, Grade A.

    Article  PubMed  PubMed Central  Google Scholar 

  8. Jongbloed F, Galassi A, Cozzolino M, Zietse R, Chiarelli G, Cusi D, Brancaccio D, Gallieni M. Clinical significance of FGF-23 measurement in dialysis patients. Clin Nephrol. 2011;76(3):201–9. Clinical Investigation, Level 3, Grade A.

    Article  CAS  PubMed  Google Scholar 

  9. Moe SM, Chertow GM, Coburn JW, Quarles LD, Goodman WG, Block GA, Drüeke TB, Cunningham J, Sherrard DJ, McCary LC, Olson KA, Turner SA, Martin KJ. Achieving NKF-K/DOQI bone metabolism and disease treatment goals with cinacalcet HCl. Kidney Int. 2005;67(2):760–71. Clinical Investigation, Level 1, Grade C.

    Article  CAS  PubMed  Google Scholar 

  10. Kidney Disease: Improving Global Outcomes (KDIGO) CKD-MBD Work Group. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease-Mineral and Bone Disorder (CKD-MBD). Kidney Int Suppl. 2009;(113):S1–130. doi:10.1038/ki.2009.188. Clinical Review, Level 1, Grade C (GUIDELINES).

    Google Scholar 

  11. Indridason OS, Quarles LD. Comparison of treatments for mild secondary hyperparathyroidism in hemodialysis patients. Durham Renal Osteodystrophy Study Group. Kidney Int. 2000;57(1):282–92. Clinical Investigation, Level 1, Grade A.

    Article  CAS  PubMed  Google Scholar 

  12. Teruel JL, Tenorio MT, Rodríguez JR, n Marc R, Orofino L, Rivera M, Ortuño J. Treatment of secondary hyperparathyroidism in hemodialyzed patients with high-dose calcium carbonate without vitamin D3 supplements. Am J Nephrol. 1999;19(3):428–32. Clinical Investigation, Level 3, Grade A.

    Article  CAS  PubMed  Google Scholar 

  13. Kalantar-Zadeh K, Kuwae N, Regidor DL, Kovesdy CP, Kilpatrick RD, Shinaberger CS, McAllister CJ, Budoff MJ, Salusky IB, Kopple JD. Survival predictability of time-varying indicators of bone disease in maintenance hemodialysis patients. Kidney Int. 2006;70(4):771–80. Clinical Investigation, Level 3, Grade A.

    Article  CAS  PubMed  Google Scholar 

  14. Block GA, Klassen PS, Lazarus JM, Ofsthun N, Lowrie EG, Chertow GM. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol. 2004;15(8):2208–18. Clinical Investigation, Level 3, Grade B.

    Article  CAS  PubMed  Google Scholar 

  15. Llach F, Massry SG. On the mechanism of secondary hyperparathyroidism in moderate renal insufficiency. J Clin Endocrinol Metab. 1985;61(4):601–6. Clinical Investigation, Level 3, Grade A.

    Article  CAS  PubMed  Google Scholar 

  16. Huml AM, Sullivan CM, Leon JB, Sehgal AR. The adequacy of phosphorus binder prescriptions among American hemodialysis patients. Ren Fail. 2012;34(10):1258–63. Clinical Investigation, Level 3, Grade A.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  17. Meric F, Yap P, Bia MJ. Etiology of hypercalcemia in hemodialysis patients on calcium carbonate therapy. Am J Kidney Dis. 1990;16(5):459–64. Clinical Investigation, Level 2, Grade B.

    Article  CAS  PubMed  Google Scholar 

  18. Bleyer AJ, Burke SK, Dillon M, Garrett B, Kant KS, Lynch D, Rahman SN, Schoenfeld P, Teitelbaum I, Zeig S, Slatopolsky E. A comparison of the calcium-free phosphate binder sevelamer hydrochloride with calcium acetate in the treatment of hyperphosphatemia in hemodialysis patients. Am J Kidney Dis. 1999;33(4):694–701. Clinical Investigation, Level 1, Grade A.

    Article  CAS  PubMed  Google Scholar 

  19. Van Buren PN, Lewis JB, Dwyer JP, Greene T, Middleton J, Sika M, Umanath K, Abraham JD, Arfeen SS, Bowline IG, Chernin G, Fadem SZ, Goral S, Koury M, Sinsakul MV, Weiner DE, Collaborative Study Group. The phosphate binder ferric citrate and mineral metabolism and inflammatory markers in maintenance dialysis patients: results from prespecified analyses of a randomized clinical trial. Am J Kidney Dis. 2015;66(3):479–88. Clinical Investigation, Level 1, Grade A.

    Article  PubMed  PubMed Central  Google Scholar 

  20. Eto N, Miyata Y, Ohno H, Yamashita T. Nicotinamide prevents the development of hyperphosphataemia by suppressing intestinal sodium-dependent phosphate transporter in rats with adenine-induced renal failure. Nephrol Dial Transplant. 2005;20(7):1378–84. Basic Science, Level 3, Grade A.

    Article  CAS  PubMed  Google Scholar 

  21. Covic A, Passlick-Deetjen J, Kroczak M, Büschges-Seraphin B, Ghenu A, Ponce P, Marzell B, de Francisco AL. A comparison of calcium acetate/magnesium carbonate and sevelamer-hydrochloride effects on fibroblast growth factor-23 and bone markers: post hoc evaluation from a controlled, randomized study. Nephrol Dial Transplant. 2013;28(9):2383–92. Clinical Investigation, Level 1, Grade A.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  22. Navaneethan SD, Palmer SC, Vecchio M, Craig JC, Elder GJ, Strippoli GF. Phosphate binders for preventing and treating bone disease in chronic kidney disease patients. Cochrane Database Syst Rev. 2011;(2):CD006023. Clinical Review, Level 1, Grade C.

    Google Scholar 

  23. Jamal SA, Vandermeer B, Raggi P, Mendelssohn DC, Chatterley T, Dorgan M, Lok CE, Fitchett D, Tsuyuki RT. Effect of calcium-based versus non-calcium-based phosphate binders on mortality in patients with chronic kidney disease: an updated systematic review and meta-analysis. Lancet. 2013;382(9900):1268–77. Clinical Review, Level 1, Grade C.

    Article  CAS  PubMed  Google Scholar 

  24. Block GA, Wheeler DC, Persky MS, Kestenbaum B, Ketteler M, Spiegel DM, Allison MA, Asplin J, Smits G, Hoofnagle AN, Kooienga L, Thadhani R, Mannstadt M, Wolf M, Chertow GM. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol. 2012;23(8):1407–15. Clinical Investigation, Level 1, Grade A.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  25. Russo D, Miranda I, Ruocco C, Battaglia Y, Buonanno E, Manzi S, Russo L, Scafarto A, Andreucci VE. The progression of coronary artery calcification in predialysis patients on calcium carbonate or sevelamer. Kidney Int. 2007;72(10):1255–61. Clinical Investigation, Level 2, Grade C.

    Article  CAS  PubMed  Google Scholar 

  26. Slatopolsky E, Brown A, Dusso A. Pathogenesis of secondary hyperparathyroidism. Kidney Int Suppl. 1999;73:S14–9. Clinical Review, Level 5.

    Article  CAS  PubMed  Google Scholar 

  27. Craver L, Marco MP, Martínez I, Rue M, Borràs M, Martín ML, Sarró F, Valdivielso JM, Fernández E. Mineral metabolism parameters throughout chronic kidney disease stages 1-5—achievement of K/DOQI target ranges. Nephrol Dial Transplant. 2007;22(4):1171–6. Clinical Investigation, Level 3, Grade B.

    Article  CAS  PubMed  Google Scholar 

  28. González EA, Sachdeva A, Oliver DA, Martin KJ. Vitamin D insufficiency and deficiency in chronic kidney disease. A single center observational study. Am J Nephrol. 2004;24(5):503–10. Clinical Investigation, Level 3, Grade B.

    Article  PubMed  Google Scholar 

  29. Gallieni M, Kamimura S, Ahmed A, Bravo E, Delmez J, Slatopolsky E, Dusso A. Kinetics of monocyte 1 alpha-hydroxylase in renal failure. Am J Physiol. 1995;268(4 Pt 2):F746–53. Basic Science, Level 3, Grade A.

    CAS  PubMed  Google Scholar 

  30. Brown AJ, Dusso AS, Slatopolsky E. Vitamin D analogues for secondary hyperparathyroidism. Nephrol Dial Transplant. 2002;17 Suppl 10:10–9. Basic Science Review, Level 2, Grade C.

    Google Scholar 

  31. Sprague SM, Llach F, Amdahl M, Taccetta C, Batlle D. Paricalcitol versus calcitriol in the treatment of secondary hyperparathyroidism. Kidney Int. 2003;63(4):1483–90. Clinical Investigation, Level 1, Grade A.

    Article  CAS  PubMed  Google Scholar 

  32. Coyne D, Acharya M, Qiu P, Abboud H, Batlle D, Rosansky S, Fadem S, Levine B, Williams L, Andress DL, Sprague SM. Paricalcitol capsule for the treatment of secondary hyperparathyroidism in stages 3 and 4 CKD. Am J Kidney Dis. 2006;47(2):263–76. Clinical Investigation, Level 1, Grade C.

    Article  CAS  PubMed  Google Scholar 

  33. Andress DL, Norris KC, Coburn JW, Slatopolsky EA, Sherrard DJ. Intravenous calcitriol in the treatment of refractory osteitis fibrosa of chronic renal failure. N Engl J Med. 1989;321(5):274–9. Clinical Investigation, Level 3, Grade A.

    Article  CAS  PubMed  Google Scholar 

  34. Park CW, Oh YS, Shin YS, Kim CM, Kim YS, Kim SY, Choi EJ, Chang YS, Bang BK. Intravenous calcitriol regresses myocardial hypertrophy in hemodialysis patients with secondary hyperparathyroidism. Am J Kidney Dis. 1999;33(1):73–81. Basic Science, Level 1, Grade B.

    Article  CAS  PubMed  Google Scholar 

  35. Kestenbaum B, Seliger SL, Gillen DL, Wasse H, Young B, Sherrard DJ, Weiss NS, Stehman-Breen CO. Parathyroidectomy rates among United States dialysis patients: 1990-1999. Kidney Int. 2004;65(1):282–8. Clinical Investigation, Level 3, Grade B.

    Article  PubMed  Google Scholar 

  36. Zheng Z, Shi H, Jia J, Li D, Lin S. Vitamin D supplementation and mortality risk in chronic kidney disease: a meta-analysis of 20 observational studies. BMC Nephrol. 2013;14:199. doi:10.1186/1471-2369-14-199. Clinical Investigation, Level 1, Grade C.

    Article  PubMed  PubMed Central  Google Scholar 

  37. Mann MC, Hobbs AJ, Hemmelgarn BR, Roberts DJ, Ahmed SB, Rabi DM. Effect of oral vitamin D analogs on mortality and cardiovascular outcomes among adults with chronic kidney disease: a meta-analysis. Clin Kidney J. 2015;8(1):41–8. Clinical Investigation, Level 1, Grade C.

    Article  PubMed  Google Scholar 

  38. Rix M, Eskildsen P, Olgaard K. Effect of 18 months of treatment with alfacalcidol on bone in patients with mild to moderate chronic renal failure. Nephrol Dial Transplant. 2004;19:870–6. Clinical Investigation, Level 1, Grade A.

    Article  CAS  PubMed  Google Scholar 

  39. Bianchi ML, Colantonio G, Campanini F, Rossi R, Valenti G, Ortolani S, Buccianti G. Calcitriol and calcium carbonate therapy in early chronic renal failure. Nephrol Dial Transplant. 1994;9(11):1595–9. Clinical Investigation, Level 2, Grade B.

    CAS  PubMed  Google Scholar 

  40. Andress DL. Adynamic bone in patients with chronic kidney disease. Kidney Int. 2008;73(12):1345–54. Clinical Review, Level 5.

    Article  CAS  PubMed  Google Scholar 

  41. Brown EM, Gamba G, Riccardi D, Lombardi D, Butters RR, Kifor O, et al. Cloning and characterization of an extracellular Ca2+-sensing receptor from bovine parathyroid. Nature. 1993;366:575–80. Basic Science, Level 1, Grade B.

    Article  CAS  PubMed  Google Scholar 

  42. Brown EM, MacLeod RJ. Extracellular Ca2+ sensing and extracellular Ca2+ signaling. Physiol Rev. 2001;81:239–97. Basic Science Review, Level 1, Grade A.

    CAS  PubMed  Google Scholar 

  43. Nemeth EF, Heaton WH, Miller M, Fox J, Balandrin MF, Van Wagenen BC, et al. Pharmacodyamics of the Type I calcimimetic compound cinacalcet HCl. J Pharmacol Exp Ther. 2004;308:627–35. Basic Science, Level 1, Grade B.

    Article  CAS  PubMed  Google Scholar 

  44. Nemeth EF. The search for calcium receptor antagonists (calcilytics). J Mol Endocrinol. 2002;29:15–22. Basic Science Review, Level 1, Grade A.

    Article  CAS  PubMed  Google Scholar 

  45. Hauache OM, Hu J, Ray K, Xie R, Jacobson KA, Spiegel AM. Effects of a calcimimetic compound and naturally activating mutations on the human Ca2+ receptor and on Ca2+ receptor/metabotropic glutamate chimeric receptors. Endocrinology. 2000;141:4156–63. Basic Science, Level 1, Grade B.

    Article  CAS  PubMed  Google Scholar 

  46. Fox J, Lowe SH, Conklin RL, Petty BA, Nemeth EF. NPS R-568: a type II calcimimetic compound that acts on parathyroid cell Ca2+ receptor of rats to reduce plasma levels of parathyroid hormone and Ca2+. J Pharmacol Exp Ther. 1999;290:473–9. Basic Science, Level 1, Grade B.

    CAS  PubMed  Google Scholar 

  47. Frazão JM, Martins P, Coburn JW. The calcimimetic agents: perspectives for treatment. Kidney Int. 2002;60:S149–54. Clinical Review, Level 1, Grade C.

    Article  Google Scholar 

  48. Sprague SM, Wetmore JB, Gurevich K, Da Roza G, Buerkert J, Reiner M, Goodman W, Cooper K. Effect of Cinacalcet and Vitamin D Analogs on Fibroblast Growth Factor-23 during the Treatment of Secondary Hyperparathyroidism.Clin J Am Soc Nephrol. 2015 Jun 5;10(6):1021–30.

    Google Scholar 

  49. Block GA, Martin KJ, de Francisco AL, Turner SA, Avram MM, Suranyi MG, Hercz G, Cunningham J, Abu-Alfa AK, Messa P, Coyne DW, Locatelli F, Cohen RM, Evenepoel P, Moe SM, Fournier A, Braun J, McCary LC, Zani VJ, Olson KA, Drüeke TB, Goodman WG. Cinacalcet for secondary hyperparathyroidism in patients receiving hemodialysis. N Engl J Med. 2004;350(15):1516–25. Clinical Investigation, Level 1, Grade A.

    Article  CAS  PubMed  Google Scholar 

  50. Chonchol M, Locatelli F, Abboud HE, Charytan C, de Francisco AL, Jolly S, Kaplan M, Roger SD, Sarkar S, Albizem MB, Mix TC, Kubo Y, Block GA. A randomized, double-blind, placebo-controlled study to assess the efficacy and safety of cinacalcet HCl in participants with CKD not receiving dialysis. Am J Kidney Dis. 2009;53(2):197–207. Clinical Investigation, Level 1, Grade A.

    Article  CAS  PubMed  Google Scholar 

  51. Charytan C, Coburn JW, Chonchol M, Herman J, Lien YH, Liu W, Klassen PS, McCary LC, Pichette V. Cinacalcet hydrochloride is an effective treatment for secondary hyperparathyroidism in patients with CKD not receiving dialysis. Am J Kidney Dis. 2005;46(1):58–67. Clinical Investigation, Level 1, Grade A.

    Article  CAS  PubMed  Google Scholar 

  52. Nakayama K, Nakao K, Takatori Y, Inoue J, Kojo S, Akagi S, Fukushima M, Wada J, Makino H. Long-term effect of cinacalcet hydrochloride on abdominal aortic calcification in patients on hemodialysis with secondary hyperparathyroidism. Int J Nephrol Renovasc Dis. 2013;7:25–33. Clinical Investigation, Level 1, Grade B.

    PubMed  PubMed Central  Google Scholar 

  53. Floege J, Kubo Y, Floege A, Chertow GM, Parfrey PS. The effect of cinacalcet on calcific uremic arteriolopathy events in patients receiving hemodialysis: The EVOLVE trial. Clin J Am Soc Nephrol. 2015;10(5):800–7. Clinical Investigation, Level 1, Grade A.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  54. Chertow GM, Block GA, Correa-Rotter R, Drüeke TB, Floege J, Goodman WG, Herzog CA, Kubo Y, London GM, Mahaffey KW, Mix TC, Moe SM, Trotman ML, Wheeler DC, Parfrey PS, EVOLVE Trial Investigators. Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med. 2012;367(26):2482–94. Clinical Investigation, Level 1, Grade A.

    Article  CAS  PubMed  Google Scholar 

  55. Ballinger AE, Palmer SC, Nistor I, Craig JC, Strippoli GF. Calcimimetics for secondary hyperparathyroidism in chronic kidney disease patients. Cochrane Database Syst Rev. 2014;(12):CD006254.

    Google Scholar 

  56. Moe SM, Abdalla S, Chertow GM, Parfrey PS, Block GA, Correa-Rotter R, Floege J, Herzog CA, London GM, Mahaffey KW, Wheeler DC, Dehmel B, Goodman WG, Drüeke TB, Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) Trial Investigators. Effects of cinacalcet on fracture events in patients receiving hemodialysis: The EVOLVE trial. J Am Soc Nephrol. 2015;26(6):1466–75. Clinical Investigation, Level 1, Grade B.

    Article  CAS  PubMed  Google Scholar 

  57. Lee YT, Ng HY, Kuo CC, Chen TC, Wu CS, Chiu TT, Lee WC, Lee CT. Comparison between calcitriol and calcitriol plus low-dose cinacalcet for the treatment of moderate to severe secondary hyperparathyroidism in chronic dialysis patients. Nutrients. 2013;5(4):1336–48. Clinical Investigation, Level 3, Grade A.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  58. Yamada S, Tokumoto M, Taniguchi M, Toyonaga J, Suehiro T, Eriguchi R, Fujimi S, Ooboshi H, Kitazono T, Tsuruya K. Two years of cinacalcet hydrochloride treatment decreased parathyroid gland volume and serum parathyroid hormone level in hemodialysis patients with advanced secondary hyperparathyroidism. Ther Apher Dial. 2015;19(4):367–77.

    Article  CAS  PubMed  Google Scholar 

  59. Cozzolino M, Ketteler M, Martin KJ, Sharma A, Goldsmith D, Khan S. Paricalcitol- or cinacalcet-centred therapy affects markers of bone mineral disease in patients with secondary hyperparathyroidism receiving haemodialysis: results of the IMPACT-SHPT study. Nephrol Dial Transplant. 2014;29(4):899–905. Clinical Investigation, Level 1, Grade A.

    Article  CAS  PubMed  Google Scholar 

  60. Roggeri DP, Cozzolino M, Mazzaferro S, Brancaccio D, Paoletti E, Roggeri A, Costanzo AM, di Luzio PU, Festa V, Messa P. Evaluating targets and costs of treatment for secondary hyperparathyroidism in incident dialysis patients: the FARO-2 study. Int J Nephrol Renovasc Dis. 2014;8:1–6. Clinical Investigation, Level 1, Grade A.

    Article  PubMed  PubMed Central  Google Scholar 

  61. Sharma A, Marshall TS, Khan SS, Johns B. Cost effectiveness of paricalcitol versus cinacalcet with low-dose vitamin D for management of secondary hyperparathyroidism in haemodialysis patients in the USA. Clin Drug Investig. 2014;34(2):107–15. Clinical Investigation, Level 2, Grade B.

    Article  CAS  PubMed  Google Scholar 

  62. Schwarz P, Body JJ, Cap J, Hofbauer LC, Farouk M, Gessl A, et al. The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice. Eur J Endocrinol. 2014;171:727–35. Clinical Investigation, Level 1, Grade B.

    Article  CAS  PubMed  Google Scholar 

  63. Saponaro F, Faggiano A, Grimaldi F, Borretta G, Brandi ML, Minisola S, et al. Cinacalcet in the management of primary hyperparathyroidism: post marketing experience of an Italian multicenter group. Clin Endocrinol (Oxf). 2013;79:20–6. Clinical Investigation, Level 2, Grade A.

    Article  CAS  Google Scholar 

  64. Khan A, Bilezikian J, Bone H, Gurevich A, Lakatos P, Misiorowski W, et al. Cinacalcet normalizes serum calcium in a double-blind randomized, placebo-controlled study in patients with primary hyperparathyroidism with contraindications to surgery. Eur J Endocrinol. 2015;172:527–35. Clinical Investigation, Level 1, Grade B.

    Article  CAS  PubMed  Google Scholar 

  65. Peacock M, Bilezikian JP, Bolognese MA, Borofsky M, Scumpia S, Sterling LR, et al. Cinacalcet HCl reduces hypercalcemia in primary hyperparathyroidism across a wide spectrum of disease severity. J Clin Endocrinol Metab. 2011;96:E9–18. Clinical Review, Level 1, Grade A.

    Article  CAS  PubMed  Google Scholar 

  66. Brardi S, Cevenini G, Verdacchi T, Romano G, Ponchietti R. Use of cinacalcet in nephrolithiasis associated with normocalcemic or hypercalcemic primary hyperparathyroidism: results of a prospective randomized pilot study. Arch Ital Urol Androl. 2015;87:66–71. Clinical Investigation, Level 1, Grade B.

    Article  PubMed  Google Scholar 

  67. Cetani F, Saponaro F, Banti C, Cianferotti L, Vignali E, Chiavistelli S, et al. Cinacalcet efficacy in patients with moderately severe hyperparathyroidism according to the European Medicine Agency prescription labeling. J Endocrinol Invest. 2012;35:655–60. Clinical Investigation, Level 1, Grade B.

    CAS  PubMed  Google Scholar 

  68. Thiem U, Gessl A, Borchhardt K. Long-term clinical practice experience with cinacalcet for treatment of hypercalcemic hyperparathyroidism after kidney transplantation. Biomed Res Int. 2015;2015:292654.

    Google Scholar 

  69. Marotta V, Di Somma C, Rubino M, Sciammarella C, Del Prete M, Marciello F, et al. Potential role of cinacalcet hydrochloride in sporadic primary hyperparathyroidism without surgery indication. Endocrine. 2015;49:274–8. Clinical Investigation, Level 1, Grade B.

    Google Scholar 

  70. Mazzaferro S, Pasquali M, Farcomeni A, Vestri AR, Filippini A, Romani AM, Barresi G, Pugliese F. Parathyroidectomy as a therapeutic tool for targeting the recommended NKF-K/DOQI ranges for serum calcium, phosphate and parathyroid hormone in dialysis patients. Nephrol Dial Transplant. 2008;23(7):2319–23. Clinical Investigation, Level 3, Grade A.

    Article  CAS  PubMed  Google Scholar 

  71. Lin HC, Chen CL, Lin HS, Chou KJ, Fang HC, Liu SI, Hsu CY, Huang WC, Huang CW, Huang CK, Chang TY, Chang YT, Lee PT. Parathyroidectomy improves cardiovascular outcome in nondiabetic dialysis patients with secondary hyperparathyroidism. Clin Endocrinol (Oxf). 2014;80(4):508–15. Clinical Investigation, Level 1, Grade A.

    Article  CAS  Google Scholar 

  72. Costa-Hong V, Jorgetti V, Gowdak LH, Moyses RM, Krieger EM, De Lima JJ. Parathyroidectomy reduces cardiovascular events and mortality in renal hyperparathyroidism. Surgery. 2007;142(5):699–703. Clinical Investigation, Level 3, Grade A.

    Article  PubMed  Google Scholar 

  73. Uhlig K, Berns JS, Kestenbaum B, Kumar R, Leonard MB, Martin KJ, Sprague SM, Goldfarb S. KDOQI US commentary on the 2009 KDIGO clinical practice guideline for the diagnosis, evaluation, and treatment of CKD-Mineral and Bone Disorder (CKD-MBD). Am J Kidney Dis. 2010;55(5):773–99. Clinical review, Level 5.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Metabolism, Endocrinology and Diabetes Department of Medicine, 24, Frank Lloyd Wright Drive, Suite 1300, Lobby C University of Michigan, Ann Arbor, 48106, USA

    Palak Choksi M.D.

  2. Department of Otolaryngology-Head and Neck Surgery, Massachusetts Eye and Ear Infirmary, 243 Charles St, Boston, MA, USA

    Bradley R. Lawson M.D.

Authors
  1. Palak Choksi M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bradley R. Lawson M.D.
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Bradley R. Lawson M.D. .

Editor information

Editors and Affiliations

  1. Department of Otolaryngology-Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA

    Brendan C. Stack, Jr.

  2. Department of Geniatrics and Otolaryngology-Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA

    Donald L. Bodenner

Rights and permissions

Reprints and permissions

Copyright information

© 2017 Springer International Publishing Switzerland

About this chapter

Cite this chapter

Choksi, P., Lawson, B.R. (2017). Secondary Hyperparathyroidism. In: Stack, Jr., B., Bodenner, D. (eds) Medical and Surgical Treatment of Parathyroid Diseases. Springer, Cham. https://doi.org/10.1007/978-3-319-26794-4_7

Download citation

  • DOI: https://doi.org/10.1007/978-3-319-26794-4_7

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-319-26792-0

  • Online ISBN: 978-3-319-26794-4

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation